Literature DB >> 26214395

Drug Manufacturers' Delayed Disclosure of Serious and Unexpected Adverse Events to the US Food and Drug Administration.

Paul Ma1, Iván Marinovic2, Pinar Karaca-Mandic3.   

Abstract

Mesh：

Year:  2015        PMID： 26214395     DOI： 10.1001/jamainternmed.2015.3565

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN： 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  5 in total

1.  Detection of Adverse Drug Reactions using Medical Named Entities on Twitter.

Authors:  Andrew MacKinlay; Hafsah Aamer; Antonio Jimeno Yepes
Journal:  AMIA Annu Symp Proc       Date:  2018-04-16

2.  A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.

Authors:  Keith B Hoffman; Mo Dimbil; Nicholas P Tatonetti; Robert F Kyle
Journal:  Drug Saf       Date:  2016-06       Impact factor: 5.606

3.  A Survey of Adverse Event Reporting Practices Among US Healthcare Professionals.

Authors:  Stella Stergiopoulos; Carrie A Brown; Thomas Felix; Gustavo Grampp; Kenneth A Getz
Journal:  Drug Saf       Date:  2016-11       Impact factor: 5.606

4.  Identification of a Syndrome Class of Neuropsychiatric Adverse Reactions to Mefloquine from Latent Class Modeling of FDA Adverse Event Reporting System Data.

Authors:  Remington L Nevin; Jeannie-Marie Leoutsakos
Journal:  Drugs R D       Date:  2017-03

5.  Complementing the US Food and Drug Administration Adverse Event Reporting System With Adverse Drug Reaction Reporting From Social Media: Comparative Analysis.

Authors:  Zeyun Zhou; Kyle Emerson Hultgren
Journal:  JMIR Public Health Surveill       Date:  2020-09-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.